EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 95 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Oligoprogression in Metastatic NSCLC Could Be Effectively Treated with SBRT Plus... December 21, 2023 Rare Melanoma Very Likely to Respond to Treatment with Pembrolizumab May 5, 2023 Maintenance Therapy with CC-486 Extends Survival of Adults with AML January 16, 2020 Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context May 22, 2026 Load more HOT NEWS Deaf Football Team Makes History, Heads To School’s First Finals Game... Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and... Ground-breaking trial pilots new tests to detect lung cancer earlier Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality...
